Developing proprietary plant-derived biomolecules to prevent metabolic diseases. Initial pipeline includes 5+ products targeting prediabetes/T2D, NAFL/NASH, hypercholesterolemia, and obesity. Lead program VALEDIA®, targeting the unaddressed prediabetes market, is currently in a Ph 2a trial for the reduction of risk factors for developing Type 2 diabetes with results expected mid 2019. In a Ph1/2 trial in healthy volunteers, VALEDIA® demonstrated a good tolerance, and during a meal test an improvement of glucose tolerance (-13% Glucose Cmax), reduction in insulin secretion (-37% Insulin AUCnet), and consequently an improvement of insulin sensitivity (41%).
Phase l or ll
Cardiovascular, Diabetes, Metabolic Disorders
12F rue Paul Vatine
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by